Physician profile
Samer Arab
NPI 1639353576
$2,354.10
in general payments reported to CMS, 2019-2025
25 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $309 · 2021: $171 · 2022: $678 · 2023: $35.19 · 2024: $297 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $595.90 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $471.95 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.61 | 2019-2022 | |
| Averitas Pharma INC. | $188.78 | 2023-2025 | Qutenza |
| Bard Peripheral Vascular, INC. | $181.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $171.58 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $106.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $75.30 | 2019-2020 | |
| Pfizer INC. | $44.60 | 2019-2024 | |
| Astellas Pharma US INC | $41.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.80 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.35 | 2025 | |
| Lilly USA, LLC | $33.15 | 2022-2024 | Mounjaro |
| Sumitomo Pharma America, INC. | $19.97 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $18.85 | 2025 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $17.88 | 2023 | Aptima, Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $17.85 | 2024 | Shingrix, Arexvy |
| Coopersurgical, INC. | $17.34 | 2025 | Paragard T 380a |
| Dexcom, INC. | $15.53 | 2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $14.54 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.97 | 2021 | |
| Exact Sciences Corporation | $13.89 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $13.60 | 2024 | Otezla, Repatha |
| Sanofi Pasteur INC. | $11.46 | 2019 | |
| Mayne Pharma Commercial LLC | $4.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Arab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.